欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的探讨甲氨蝶呤（MTX）治疗寻常性银屑病（PV）的疗效及对患者血清IL-23，IL-17的影响，进一步阐明MTX治疗PV的作用机制.方法应用ELISA方法检测42例寻常性银屑痛患者经MXT治疗前后血清IL-23，IL-17水平变化，并与4l例正常对照组比较。结果MTX治疗寻常性银屑病疗效显著，治疗后PASI评分显著下降（P〈0．01）。患者血清IL-23，IL-17水平分别为（1581．16±463．31）ng／L和（7．44±2．36）ng／L，显著高于正常对照组的（832．41±309．16）ng／L和（2．93±O．85）ng／L，差异有统计学意义（P〈0．01）MTX治疗后患者血清IL-23，IL-17水平分别为（845．68±385．95）ng／L和（3．04±0．79）ng／L，与治疗前相比显著下降，差异有统计学意义（P〈0．叭），且患者血清IL-23，IL-17水平与银屑病PASI评分均呈显著正相关（P〈0．01）。结论MTX治疗寻常性银屑病疗效显著，可能通过调节Th17细胞降低血清IL-23，IL-17水平发挥治疗作用，
英文摘要：
Objective To investigate the therapeutic effect of methotrexate （MTX） on psoriasis vulgaris （ PV）, study the effect of MTX on serum levels of IL-23 and IL-17, and further clarify the mechanism of MTX. Methods Serum levels of IL-23 and IL-17 in 42 patients with PV （ before and ＇after treatment hy MTX） and 41 healthy controls were measured by ELISA. Results The mean PASI scores were significantly decreased ＇af- ter treatment with MTX （P 〈0. 01 ）. Serum levels of IL-23 and IL-17 of PV patients were 1561.91±501.84 ng/L and 7. 87±2.41 ng/L, respectively. Which were both significantly higher than those in healthy con- trois （796.59 ± 342. 61 ng/L and 2.91±0. 71 ng/L,P 〈0. 01 ）. After treatment with MTX,Serum levels of IL-23 and IL-17 of PV patients were 845.68 ± 385.95 ng,/L and 3.04 ± 0. 79 ng/L, respeetively. Which were both significantly decreased than those before treatment. Serum levels of IL-23 and IL-17 of PV patients were both associated with PASI （P 〈 0.01 ）. Conclusion MTX is significantly effective in the treatment of PV. It may ＇affect serum levels of IL-23 and IL-17 by regulating Thl7 cells to play a role in the treatment of
同期刊论文项目
同项目期刊论文
期刊信息
位置：